نتایج جستجو برای: gemtuzumab ozogamicin
تعداد نتایج: 479 فیلتر نتایج به سال:
We report a case of pulmonary veno-occlusive disease (PVOD) following allogeneic bone marrow transplantation (BMT) for the treatment of acute myeloid leukemia (AML) from an HLA mismatched mother using a reduced-intensity conditioning (RIC) regimen including gemtuzumab ozogamicin. The patient was a 21-year-old male who complained of dyspnea with hypoxemia followed by loss of consciousness. The a...
Long-term survival of relapsed/refractory acute myeloid leukemia (AML) remains a major problem, particularly in patients not eligible for transplantation.We hereby evaluated the feasibility and efficacy of adding Gemtuzumab Ozogamicin to salvage chemotherapy (Ara-C, Idarubicine, Peg-Filgrastim) in relapsed/refractory AML. The main endpoints were: the rate of complete remissions (CR) and the pro...
Az akut mieloid leukémia kezelésének új lehetőségei: út a személyre szabott terápiás stratégiák felé
Az akut mieloid leukémia (AML) kezelésének arany standardja évtizedek óta az intenzív kemoterápia, azonban erre nem alkalmas vagy refrakter betegeknél jelenleg nincs más kuratív lehetőség. utóbbi évek gyógyszerfejlesztése a jó és rosszabb általános állapotú eseteknél is kibővítette terápiás armamentáriumot, új lehetőségeket kihívásokat teremtve. szerek közé tartozik például venetoclax, IDH1/2 g...
The development of molecular studies to define the somatic genetic alterations has revolutionized diagnostic and therapeutic management acute myeloid leukemia (AML). AML is a highly heterogenous disease that includes many subtypes; each subtype heterogeneous both for presence variable co-mutations complex combinations clones subclones, changing during evolution in response treatment. treatment ...
Gemtuzumab ozogamicin (GO) is a humanized anti-CD33 monoclonal antibody conjugated to a derivative of an antitumor antibiotic, calicheamicin. GO was approved for the treatment of relapsed acute myeloid leukemia (AML) in the United States (US) in 2000. However, GO was withdrawn from the US market in June 2010, because a large-scale clinical trial failed to show additive or synergistic effects wi...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید